Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Wang on the Pace of Progress in MCL

June 25th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL

June 22nd 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

Expert Makes Case for Frontline Targeted Therapy in Select MCL Subtypes

June 21st 2019

Ezzat Elhassadi, MD, highlights research being done to address the unmet need of patients with p53-mutant mantle cell lymphoma and the challenges faced in the current treatment paradigm.

Dr. Song on Zanubrutinib Activity in Relapsed/Refractory MCL

June 21st 2019

Yuqin Song, MD, PhD, chief physician and deputy director of the Lymphoma Department at Peking University Cancer Hospital, Beijing, China, discusses the updated data from the phase II trial evaluating the efficacy of zanubrutinib (BGB-3111-206) in patients with relapsed/refractory mantle cell lymphoma.

Dr. McCulloch on Data Supporting the Use of R-BAC in MCL

June 21st 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses data supporting the use of R-BAC (rituximab [Rituxan], cytarabine, and bendamustine) in mantle cell lymphoma (MCL).

Dr. Elhassadi Discusses the Outlook of Patients With p53-Mutated MCL

June 19th 2019

Ezzat Elhassadi, MD, consultant hematologist, Haematology Services, University Hospital Waterford, discusses the outlook of patients with p53-mutated mantle cell lymphoma.

Lead Investigator Shares Early Data With Ibrutinib Maintenance in MCL

June 19th 2019

Reem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.

Dr. Fenske Discusses Ongoing Study in Frontline MCL

June 19th 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses an ongoing study in the frontline treatment of mantle cell lymphoma.

Dr. Karmali on Novel Agents in Relapsed/Refractory MCL

June 14th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Wang on Challenges Treating Patients With Relapsed/Refractory MCL

June 13th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Karmali on Ibrutinib Maintenance Following Induction in Untreated MCL

June 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the preliminary results of a study which examined ibrutinib (Imbruvica) maintenance following induction in treatment-naïve patients with mantle cell lymphoma (MCL).

Dr. McKinney Discusses Ongoing Work in MCL

June 6th 2019

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses ongoing work in mantle cell lymphoma.

Dr. Fenske Discusses Targets Under Evaluation in MCL

June 5th 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Pipeline Updates Advance Paradigms Across Lymphomas

May 31st 2019

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

Dr. McKinney Discusses the Watch-and-Wait Approach in MCL

May 29th 2019

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses the watch-and-wait approach in mantle cell lymphoma.

Dr. Wang Discusses the Future of Treatment in MCL

May 24th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

MCL Landscape Rapidly Evolving With Promising Approaches on Horizon

May 24th 2019

Ann S. LaCasce, MD, MMSc, highlights recent progress made in MCL, exciting approaches under investigation, and provides insight into where future research should focus.

Small Molecule Shows Marked Activity Against Ibrutinib-Resistant MCL

May 17th 2019

Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.

Dr. Fenske on the Future of Daratumumab in MCL

May 7th 2019

Timothy Fenske, MD, MS, associate professor, Medical College of Wisconsin, discusses the future of daratumumab (Darzalex) in mantle cell lymphoma (MCL).

MCL Treatment Paradigm Expands With Novel Combos

May 1st 2019

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.